Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial - Zhu, A X; Finn, R S; Edeline, J (Lancet Oncol, 2018)
et al.